These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 28284333)

  • 1. Serum soluble Talin-1 levels are elevated in patients with multiple sclerosis, reflecting its disease activity.
    Muto M; Mori M; Liu J; Uzawa A; Uchida T; Masuda H; Ohtani R; Sugimoto K; Kuwabara S
    J Neuroimmunol; 2017 Apr; 305():131-134. PubMed ID: 28284333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel serum autoantibodies against talin1 in multiple sclerosis: Possible pathogenetic roles of the antibodies.
    Muto M; Mori M; Hiwasa T; Takiguchi M; Iwadate Y; Uzawa A; Uchida T; Masuda H; Sugimoto K; Kuwabara S
    J Neuroimmunol; 2015 Jul; 284():30-6. PubMed ID: 26025055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase in interleukin-6 levels is related to depressive phenomena in the acute (relapsing) phase of multiple sclerosis.
    Koutsouraki E; Hatzifilipou E; Michmizos D; Cotsavasiloglou C; Costa V; Baloyannis S
    J Neuropsychiatry Clin Neurosci; 2011; 23(4):442-8. PubMed ID: 22231316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgM to S-nitrosylated protein is found intrathecally in relapsing-remitting multiple sclerosis.
    Hvaring C; Vujicic S; Aasly JO; Feinstein DL; White LR; Boullerne AI
    J Neuroimmunol; 2013 Mar; 256(1-2):77-83. PubMed ID: 23351705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis.
    Castellazzi M; Tamborino C; Cani A; Negri E; Baldi E; Seraceni S; Tola MR; Granieri E; Contini C; Fainardi E
    Mult Scler; 2010 Jul; 16(7):883-7. PubMed ID: 20483883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Plasma Levels of Soluble Talin-1 in Patients with Coronary Artery Disease.
    Aoyama M; Kishimoto Y; Saita E; Ikegami Y; Ohmori R; Nakamura M; Kondo K; Momiyama Y
    Dis Markers; 2020; 2020():2479830. PubMed ID: 32566035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble L-selectin levels in serum and cerebrospinal fluid in patients with multiple sclerosis and systemic lupus erythematosus.
    Baraczka K; Pozsonyi T; Nékám K; Virányi M; Seszták M; Szongoth M; Jakab L
    Acta Neurol Scand; 2000 Aug; 102(2):114-7. PubMed ID: 10949528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of sTNFR-1 and sFas in patients with relapsing-remitting multiple sclerosis.
    Bilińska M; Frydecka I; Podemski R; Gruszka E
    Med Sci Monit; 2002 Oct; 8(10):CR720-3. PubMed ID: 12388926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients.
    Lanzillo R; Di Somma C; Quarantelli M; Ventrella G; Gasperi M; Prinster A; Vacca G; Pivonello C; Orefice G; Colao A; Morra VB
    Eur J Neurol; 2011 Dec; 18(12):1402-6. PubMed ID: 21585623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
    Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Govoni V; Caniatti L; Paolino E; Tola MR; Granieri E; Baricordi OR
    J Neuroimmunol; 2004 Mar; 148(1-2):206-11. PubMed ID: 14975603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of cladribine on soluble adhesion molecules in multiple sclerosis.
    Mitosek-Szewczyk K; Stelmasiak Z; Bartosik-Psujek H; Belniak E
    Acta Neurol Scand; 2010 Dec; 122(6):409-13. PubMed ID: 20175758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased serum levels of soluble CD14 indicate stable multiple sclerosis.
    Lutterotti A; Kuenz B; Gredler V; Khalil M; Ehling R; Gneiss C; Egg R; Deisenhammer F; Berger T; Reindl M
    J Neuroimmunol; 2006 Dec; 181(1-2):145-9. PubMed ID: 17046070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum uric acid level in patients with relapsing-remitting multiple sclerosis.
    Ashtari F; Bahar M; Aghaei M; Zahed A
    J Clin Neurosci; 2013 May; 20(5):676-8. PubMed ID: 23528410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index.
    de Bock L; Fraussen J; Villar LM; Álvarez-Cermeño JC; Van Wijmeersch B; van Pesch V; Stinissen P; Somers V
    Eur J Neurol; 2016 Apr; 23(4):722-8. PubMed ID: 26706657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D is associated with degree of disability in patients with fully ambulatory relapsing-remitting multiple sclerosis.
    Thouvenot E; Orsini M; Daures JP; Camu W
    Eur J Neurol; 2015 Mar; 22(3):564-9. PubMed ID: 25530281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe disability in patients with relapsing-remitting multiple sclerosis is associated with profound changes in the regulation of leptin secretion.
    Rotondi M; Batocchi AP; Coperchini F; Caggiula M; Zerbini F; Sideri R; Leporati P; Nociti V; Frisullo G; Mirabella M; Magri F; Oliviero A; Chiovato L
    Neuroimmunomodulation; 2013; 20(6):341-7. PubMed ID: 24008588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS.
    Sisay S; Lopez-Lozano L; Mickunas M; Quiroga-Fernández A; Palace J; Warnes G; Alvarez-Lafuente R; Dua P; Meier UC
    J Neuroimmunol; 2017 May; 306():40-45. PubMed ID: 28385186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of soluble ICAM-1 and TNFalphaR in the cerebrospinal fluid and serum levels in a population of Brazilian patients with relapsing-remitting multiple sclerosis.
    Alves-Leon SV; Batista E; Papais-Alvarenga R; Quírico-Santos T
    Arq Neuropsiquiatr; 2001 Mar; 59(1):18-22. PubMed ID: 11299425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.
    Fainardi E; Castellazzi M; Bellini T; Manfrinato MC; Baldi E; Casetta I; Paolino E; Granieri E; Dallocchio F
    Mult Scler; 2006 Jun; 12(3):294-301. PubMed ID: 16764342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis.
    Szmyrka-Kaczmarek M; Pokryszko-Dragan A; Pawlik B; Gruszka E; Korman L; Podemski R; Wiland P; Szechinski J
    Lupus; 2012 Apr; 21(4):412-20. PubMed ID: 22074845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.